Dougall WC - Search Results

1

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Lacey DL, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J, Dansey R. Lacey DL, et al. Among authors: dougall wc. Nat Rev Drug Discov. 2012 May;11(5):401-19. doi: 10.1038/nrd3705. Nat Rev Drug Discov. 2012. PMID: 22543469 Review.

2

[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].

Dougall W, Chaisson M. Dougall W, et al. Clin Calcium. 2006 Apr;16(4):627- 35. Clin Calcium. 2006. PMID: 16582514 Review. Japanese.

3

The RANK/RANKL/OPG triad in cancer-induced bone diseases.

Dougall WC, Chaisson M. Dougall WC, et al. Cancer Metastasis Rev. 2006 Dec;25(4):541-9. doi: 10.1007/s10555-006-9021-3. Cancer Metastasis Rev. 2006. PMID: 17180711 Review.

4

RANKL inhibition: from mice to men (and women).

Stolina M, Kostenuik PJ, Dougall WC, Fitzpatrick LA, Zack DJ. Stolina M, et al. Among authors: dougall wc. Adv Exp Med Biol. 2007;602:143-50. doi: 10.1007/978-0-387-72009-8_18. Adv Exp Med Biol. 2007. PMID: 17966399 Review.

5

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Armstrong AP, Miller RE, Jones JC, Zhang J, Keller ET, Dougall WC. Armstrong AP, et al. Among authors: dougall wc. Prostate. 2008 Jan 1;68(1):92-104. doi: 10.1002/pros.20678. Prostate. 2008. PMID: 18008334 Free article.

6

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.

Canon JR, Roudier M, Bryant R, Morony S, Stolina M, Kostenuik PJ, Dougall WC. Canon JR, et al. Among authors: dougall wc. Clin Exp Metastasis. 2008;25(2):119-29. doi: 10.1007/s10585-007-9127-1. Epub 2007 Dec 5. Clin Exp Metastasis. 2008. PMID: 18064531

7

RANKL signaling in bone physiology and cancer.

Dougall WC. Dougall WC. Curr Opin Support Palliat Care. 2007 Dec;1(4):317-22. doi: 10.1097/SPC.0b013e3282f335be. Curr Opin Support Palliat Care. 2007. PMID: 18685382 Review.

8

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C, Sun N, Chen C, Li L, Cattley RC, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan HL, Asuncion F, Li X, Ominsky MS, Stolina M, Dwyer D, Dougall WC, Hawkins N, Boyle WJ, Simonet WS, Sullivan JK. Kostenuik PJ, et al. Among authors: dougall wc. J Bone Miner Res. 2009 Feb;24(2):182-95. doi: 10.1359/jbmr.081112. J Bone Miner Res. 2009. PMID: 19016581 Free article.

9

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. Gonzalez-Suarez E, et al. Among authors: dougall wc. Nature. 2010 Nov 4;468(7320):103-7. doi: 10.1038/nature09495. Epub 2010 Sep 29. Nature. 2010. PMID: 20881963

10

Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.

Dougall WC. Dougall WC. Clin Cancer Res. 2012 Jan 15;18(2):326-35. doi: 10.1158/1078-0432.CCR-10-2507. Epub 2011 Oct 26. Clin Cancer Res. 2012. PMID: 22031096

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

94 results

Search Page